Ketamine continues to gain in popularity as an off-label treatment for mood disorders. During the pandemic, remote telepsychiatry companies have gained in popularity, facilitating remote prescribing of sublingual ketamine. That practice may change on May 11, when the White House plans to end the COVID-19 public health emergency (PHE). The PHE enabled companies such as…